CN115991703A - 并环化合物及其制备方法、药物组合物和应用 - Google Patents

并环化合物及其制备方法、药物组合物和应用 Download PDF

Info

Publication number
CN115991703A
CN115991703A CN202211412069.6A CN202211412069A CN115991703A CN 115991703 A CN115991703 A CN 115991703A CN 202211412069 A CN202211412069 A CN 202211412069A CN 115991703 A CN115991703 A CN 115991703A
Authority
CN
China
Prior art keywords
alkyl
halogenated
carbocyclyl
independently selected
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211412069.6A
Other languages
English (en)
Chinese (zh)
Inventor
邓代国
邱关鹏
王永钢
雷曾荣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Fermizi Technology Co ltd
Original Assignee
Guangzhou Fermizi Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Fermizi Technology Co ltd filed Critical Guangzhou Fermizi Technology Co ltd
Publication of CN115991703A publication Critical patent/CN115991703A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202211412069.6A 2020-05-21 2021-05-21 并环化合物及其制备方法、药物组合物和应用 Pending CN115991703A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020104339886 2020-05-21
CN202010433988 2020-05-21
CN202110529033 2021-05-14
CN2021105290335 2021-05-14
CN202110556640.0A CN113717167B (zh) 2020-05-21 2021-05-21 并环化合物及其制备方法、药物组合物和应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202110556640.0A Division CN113717167B (zh) 2020-05-21 2021-05-21 并环化合物及其制备方法、药物组合物和应用

Publications (1)

Publication Number Publication Date
CN115991703A true CN115991703A (zh) 2023-04-21

Family

ID=78672734

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211412069.6A Pending CN115991703A (zh) 2020-05-21 2021-05-21 并环化合物及其制备方法、药物组合物和应用
CN202110556640.0A Active CN113717167B (zh) 2020-05-21 2021-05-21 并环化合物及其制备方法、药物组合物和应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110556640.0A Active CN113717167B (zh) 2020-05-21 2021-05-21 并环化合物及其制备方法、药物组合物和应用

Country Status (8)

Country Link
US (1) US20230192683A1 (https=)
EP (1) EP4155305A4 (https=)
JP (1) JP7774312B2 (https=)
KR (1) KR20230015333A (https=)
CN (2) CN115991703A (https=)
AU (1) AU2021276301A1 (https=)
TW (1) TWI910166B (https=)
WO (1) WO2021233427A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI860849B (zh) 2021-09-14 2024-11-01 美商美國禮來大藥廠 Sstr4促效劑鹽
KR20240122964A (ko) 2023-02-06 2024-08-13 에이치엘만도 주식회사 피스톤 밸브 조립체 및 이를 구비한 쇼크 업소버
JP2026509366A (ja) 2023-03-10 2026-03-18 イーライ リリー アンド カンパニー Ｓｓｔｒ４アゴニスト及びその塩の調製のための方法
AU2024236692A1 (en) 2023-03-10 2025-10-16 Eli Lilly And Company Methods for the preparation and dose regimens for use of sstr4 agonists and salts thereof
WO2024245077A1 (zh) * 2023-05-29 2024-12-05 武汉熙瑞医药科技有限公司 3-氮杂-双环[3.1.0]己烷衍生物、其制备方法及其应用
WO2025096300A1 (en) 2023-10-30 2025-05-08 Eli Lilly And Company Novel methods for the preparation of 3-azabicylco[3.1,0]hexane-6-carboxamide derivatives
CN120965687A (zh) * 2024-05-17 2025-11-18 广州费米子科技有限责任公司 Sstr4激动剂类化合物的晶体形式及其制备方法和用途
WO2025247982A1 (en) 2024-05-29 2025-12-04 Grünenthal GmbH Piperazines which act as sstr4 modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2685828A4 (en) * 2011-03-17 2014-08-13 Merck Sharp & Dohme SUBSTITUTED 3-AZABICYCLO [3,1,0-] HEXAN DERIVATIVES AS CCR2 ANTAGONISTS
KR101556318B1 (ko) * 2013-05-15 2015-10-01 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 6-피라졸일아미도-3-치환된 아자바이사이클로[3.1.0]헥산 유도체
US9371282B2 (en) * 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
EP3045448A4 (en) 2013-09-12 2017-01-25 Sumitomo Chemical Company Limited Nitrogen-containing saturated heterocyclic compound
CN105315293A (zh) * 2014-07-29 2016-02-10 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环化合物及其制备方法和用途

Also Published As

Publication number Publication date
WO2021233427A1 (zh) 2021-11-25
JP7774312B2 (ja) 2025-11-21
US20230192683A1 (en) 2023-06-22
EP4155305A4 (en) 2024-07-10
TW202146402A (zh) 2021-12-16
TWI910166B (zh) 2026-01-01
EP4155305A1 (en) 2023-03-29
AU2021276301A1 (en) 2023-01-19
JP2023526791A (ja) 2023-06-23
CN113717167B (zh) 2022-12-02
CN113717167A (zh) 2021-11-30
KR20230015333A (ko) 2023-01-31

Similar Documents

Publication Publication Date Title
CN115991703A (zh) 并环化合物及其制备方法、药物组合物和应用
CN113929693B (zh) 含氮杂环化合物、药物组合物和应用
CN116375742A (zh) 一种氮杂芳环衍生物及其组合物和药学上的应用
CN113717161B (zh) 含氮饱和杂环化合物及其制备方法、药物组合物和应用
EP4450500A1 (en) Tricyclic fused heterocyclic pde3/4 dual inhibitor and use thereof
CN118955496B (zh) 一种化合物及其应用
JP2023516235A (ja) Ｓｓｔｒ５アンタゴニスト
CN120208924B (zh) 用作电压-门控钠通道抑制剂的化合物
EP3375781A1 (en) Benzo ring derivative with b2 receptor agonist and m3 receptor antagonist activities and use thereof in medicine
EP4269404A1 (en) Ketohexokinase inhibitor and use thereof
TW202416964A (zh) 製備激酶抑制劑之方法
CN117651703A (zh) 取代的氨基甲酸大环化合物及其相关治疗方法
CN116640157A (zh) 一种mettl3抑制剂及其组合物及其在医药上的应用
CN114685520B (zh) 三并环化合物及其药物组合物和应用
CN118496202A (zh) 生长抑制素受体亚型4(sstr4)激动剂
CN112778274B (zh) 一种含氮杂环衍生物及其制备
EP3186232B1 (en) P38 map kinase inhibiting indanyl urea compounds
HK40062713B (en) Fused-ring compounds, preparation method, pharmaceutical composition and use thereof
TWI916367B (zh) 含氮飽和雜環化合物及其製備方法、藥物組合物和應用
HK40062713A (en) Fused-ring compounds, preparation method, pharmaceutical composition and use thereof
CN116437917B (zh) Atx抑制剂氘代衍生物及其应用
CN119019378A (zh) 一种杂环衍生物及其组合物和药学上的应用
CN119490501A (zh) 咪唑双环化合物及其制备方法和用途
WO2025148997A1 (zh) 一种四氢吡啶并吡唑衍生物及其在医药上的应用
CN115724846A (zh) 异喹啉磺酰衍生物新晶型及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination